glp 1 agonists review GLP1 agonists: current and future landscape of clinical trials for patients with metabolic dysfunction A clinician's perspective 📝 GLP-1

Additionally, GLP-1 agonists enhance insulin signaling in the periphery and in the brain which may improve vascular dementia through improved glucose metabolism in the brain and decreased neuroinflammation [13]

R.B wrote main manuscript text, and created Table 3

A.FowlerD

Confirmatory large-scale trials are essential to ascertain the potential efficacy of GLP-1RAs in specifically improving the stroke outcomes

A higher dose of liraglutide, up to 3 mg daily (Saxenda), has been approved by the US FDA for weight management in certain obese or overweight individuals

Regulatory Approvals and Expanded Indications: Growing regulatory approvals and treatment guidelines for GLP-1 therapies further enhance market adoption, particularly for patients with co-morbidities like obesity